Acurx PharmaceuticalsACXP
ACXP
About: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Employees: 4
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
567% more call options, than puts
Call options by funds: $20K | Put options by funds: $3K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
19% more funds holding
Funds holding: 21 [Q3] → 25 (+4) [Q4]
0.67% more ownership
Funds ownership: 7.68% [Q3] → 8.35% (+0.67%) [Q4]
51% less capital invested
Capital invested by funds: $2.37M [Q3] → $1.16M (-$1.21M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
3,119%
upside
Avg. target
$12
3,119%
upside
High target
$12
3,119%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target | 3,119%upside $12 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ACXP published over the past 30 days
Neutral
PRNewsWire
2 days ago
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.
Positive
Zacks Investment Research
1 week ago
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Positive
Zacks Investment Research
4 weeks ago
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
1 month ago
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Claire Acheson - Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Neutral
PRNewsWire
1 month ago
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
STATEN ISLAND, N.Y. , March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2024.
Neutral
PRNewsWire
1 month ago
Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
STATEN ISLAND, N.Y. , March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof).
Neutral
PRNewsWire
1 month ago
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
STATEN ISLAND, N.Y. , March 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof) in a registered direct offering.
Neutral
PRNewsWire
1 month ago
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity Notable differences were observed between the microbiome of IBZ- and fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI IBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y. , March 3, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C.
Neutral
PRNewsWire
1 month ago
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open.
Neutral
PRNewsWire
1 month ago
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resistant to IBZ, allowing regrowth of resistant microbes known to confer health benefits This study used in silico methods to better interpret the narrower than expected ibezapolstat (IBZ) spectrum of activity observed in human trials, which included increased proportion of certain key gut microbiota of the Bacillota phylum IBZ susceptibility of human commensal (nonpathogenic) microbiota was predicted using genomic analysis and a phylogenetic tree construction of the IBZ target enzyme, pol IIIC Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI IBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
Charts implemented using Lightweight Charts™